Author

C. Van Waes

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Y. Robbins· 2 shared B. Bernard· 1 shared B. Carter· 1 shared C. Allen· 1 shared C. Chen· 1 shared C. Sievers· 1 shared C. T. Allen· 1 shared D. Tsai· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Y. Robbins

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Epigenetic silencing by SMYD3 represses tumor intrinsic interferon response in HPV-negative squamous cell carcinoma of the head and neck.

N. Nigam, B. Bernard, S. Kim, K. Burkitt, D. Tsai, Y. Robbins, C. Sievers, C. T. Allen, R. L. Bennett, T. T. Tettey, B. Carter, R. Bao, L. Rinaldi, M. W. Lingen, H. Sater, , V. Saloura

This study identifies SMYD3 as an epigenetic regulator that suppresses the intrinsic interferon response in HPV-negative HNSCC, offering a potential strategy to enhance immunotherapy response.

bioRxiv · Nov 4, 2022 · PreprintCancer Biology

Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells

Y. Robbins, S. Greene, J. Friedman, P. E. Clavijo, C. Van Waes, K. P. Fabian, M. R. Padget, H. Abdul Sater, J. H. Lee, P. Soon-Shiong, J. Gulley, J. Schlom, J. Hodge, C. Allen

This study shows PD-L1 CAR-engineered NK cells kill cancer cells and inhibit tumor growth by targeting PD-L1, reducing myeloid cells in both preclinical models and patient blood.

bioRxiv · Jan 30, 2020Immunology